Sector News

Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors

November 4, 2015
Life sciences

The Novartis Board of Directors announced today, that it is nominating Ms. Elizabeth Doherty and Mr. Ton Buechner for election to the Board at the Annual General Meeting (AGM) of Shareholders to be held on February 23, 2016.

Ms. Doherty is a finance professional with a career spanning more than 35 years in the fast moving consumer goods industry where she developed strategies and programs to improve business outcomes and drive shareholder value. Ms. Doherty is a British national and seasoned professional having served as a CFO and member of the Board of Directors on numerous corporations.

Mr. Buechner is the CEO and Chairman of the Executive Board of AkzoNobel, a Dutch multinational active in the fields of decorative paints, performance coatings and specialty chemicals. As a business leader and engineer by training, Mr. Buechner has successfully led global companies with portfolios targeting both business to business and direct to consumer activities.

Source: Novartis

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend